Avricore Health Inc.

corporate_fare Company Profile

Avricore Health Inc.

AVCRF·OTC·Life Sciences·CIK 0001355736

Duft Biotech Capital Ltd. was incorporated on May 30, 2000, under the BC Companies Act. The company was classified as a Capital Pool Company ("CPC") on the TSX Venture Exchange. As a CPC, its primary business was to identify and evaluate acquisition opportunities, with the completion of such an acquisition referred to as a Qualifying Transaction. A CPC does not conduct any business operations or hold assets other than seed capital, and it does not have agreements for asset or business acquisition at its formation. A Qualifying Transaction, as defined by TSX Venture Exchange policies, involves a capital pool company either issuing common shares or convertible securities representing over 25 percent of its outstanding common shares for significant assets or businesses, entering into an arrangement where another issuer's security holders gain control of the resulting entity, or otherwise acquiring significant non-cash assets. On November 13, 2003, the company acquired the assets of ALDA Pharmaceuticals Inc. ("API"), a private company established in 1996.

Avricore Health Inc. (OTC:AVCRF) is a publicly traded company in the Life Sciences sector. Wiseek monitors AVCRF SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Avricore Health Secures $1.25M Private Placement to Address Going Concern (2026-06-11)
Avricore Health Faces Going Concern Warning Amidst 89% Revenue Drop and Increased Losses (2026-05-08)
Avricore Health's HealthTab™ Expands to 70 New Pharmacy Sites in North East London NHS Program (2026-02-17)
Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss (2026-01-12)

Financial Snapshot

Fiscal year ended December 31, 2024

Revenue

CA$4.66M CAD

Net Income

-CA$668.98K CAD

Diluted EPS

-CA$0.01 CAD

Op. Cash Flow

CA$1M CAD

Free Cash Flow

CA$823.52K CAD

Gross Profit

CA$1.88M CAD

Cash & Equivalents

CA$1.13M CAD

Debt / Equity

0.00×

Net Margin

-14.4%

Source: 20-F · filed 2025-06-16 · accession 0001641172-25-015266

Insider Transactions

AVCRF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →

show_chartPrice Chart

Loading chart...

feed AVCRF - Latest Insights

Filing Type

Date Range

AVCRF

Jun 11, 2026, 6:12 AM EDT

Filing Type: 6-K

Importance Score:

Avricore Health Secures $1.25M Private Placement to Address Going Concern

Price at Filing: $0.04965

Real-time Price: $0.04575

Change: -$0.0039 (-8%)

Market Cap: $4.634M

Sentiment: Neutral

View Wiseek Article

AVCRF

May 08, 2026, 7:01 PM EDT

Filing Type: 6-K

Importance Score:

Avricore Health Faces Going Concern Warning Amidst 89% Revenue Drop and Increased Losses

Price at Filing: $0.0399

Real-time Price: $0.04575

Change: +$0.00585 (+15%)

Market Cap: $4.634M

Sentiment: Negative

View Wiseek Article

AVCRF

Feb 17, 2026, 6:15 AM EST

Filing Type: 6-K

Importance Score:

Avricore Health's HealthTab™ Expands to 70 New Pharmacy Sites in North East London NHS Program

Price at Filing: $0.0529

Real-time Price: $0.04575

Change: -$0.00715 (-14%)

Market Cap: $4.634M

Sentiment: Positive

View Wiseek Article

AVCRF

Jan 12, 2026, 3:09 PM EST

Filing Type: 6-K

Importance Score:

Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss

Price at Filing: $0.03525

Real-time Price: $0.04575

Change: +$0.0105 (+30%)

Market Cap: $4.634M

Sentiment: Negative

View Wiseek Article

corporate_fare Company Profile